Overview
Congenital herpes simplex virus (HSV) infection is a rare but severe condition affecting newborns, typically acquired during vaginal delivery from an infected mother. This infection can manifest as neonatal herpes, which includes localized, disseminated, or central nervous system (CNS) involvement, often leading to significant morbidity and mortality if untreated. The clinical significance lies in its rapid progression and high fatality rate without prompt intervention. Neonates are particularly vulnerable due to their immature immune systems. Early recognition and aggressive treatment are crucial in day-to-day practice to improve outcomes and reduce mortality rates 14.Pathophysiology
Congenital HSV infection arises from vertical transmission during delivery, primarily through ascending infection from the genital tract. Once introduced into the neonate, the virus exploits host cell machinery to replicate, often targeting epithelial cells and neurons due to their high expression of specific receptors like those for herpesviruses. Unlike many other herpesviruses, HSV does not significantly downregulate major histocompatibility complex (MHC) class I molecules, which might explain its robust immune detection but also underscores the rapid viral spread before immune responses are fully mounted 1. The virus can quickly disseminate via hematogenous spread, affecting multiple organ systems including the skin, eyes, mouth, liver, lungs, and central nervous system (CNS). This systemic involvement is driven by the virus's ability to evade initial immune surveillance while efficiently replicating and spreading, leading to severe clinical manifestations 14.Epidemiology
The incidence of congenital HSV infection is relatively low, estimated at approximately 1 in 3,000 to 1 in 10,000 live births, though this can vary based on geographical and demographic factors 1. Neonates are predominantly affected, with no significant sex predilection noted. Risk factors include maternal primary HSV infection during pregnancy, as reactivation rates are higher compared to those with preexisting immunity. Geographic regions with higher HSV seroprevalence in the general population may see increased incidence rates. Trends suggest that improved antenatal screening and counseling have not significantly altered the incidence but have enhanced early detection and management 14.Clinical Presentation
Neonates with congenital HSV infection can present with a wide spectrum of symptoms, ranging from subtle to severe. Typical presentations include vesicular rash, often around the eyes, mouth, and skin, indicative of localized infection. Atypical presentations may include fever, irritability, poor feeding, seizures, lethargy, and signs of systemic involvement such as respiratory distress or hepatosplenomegaly. Red-flag features include vesicular lesions in atypical locations, CNS symptoms like altered mental status, and disseminated disease with multi-organ involvement. Early recognition of these signs is critical for timely intervention 14.Diagnosis
The diagnosis of congenital HSV infection involves a combination of clinical suspicion, laboratory testing, and imaging. Initial steps include detailed clinical evaluation focusing on neonatal history and physical examination findings suggestive of HSV infection. Specific diagnostic criteria and tests include:Differential Diagnosis:
Management
First-Line Treatment
Second-Line Treatment
Specialist Escalation
Contraindications:
Complications
Common complications include:Referral to specialists is warranted when complications such as CNS involvement or severe ocular symptoms are observed to ensure timely and appropriate management 14.
Prognosis & Follow-up
The prognosis for neonates with congenital HSV infection varies widely depending on the severity and timing of diagnosis and treatment. Early intervention significantly improves outcomes, with survival rates approaching 90% for localized infections but dropping to 30-50% for disseminated or CNS involvement 14. Prognostic indicators include the extent of CNS involvement and the presence of disseminated disease. Recommended follow-up includes:Special Populations
Pregnancy and Neonatal Care
Pediatric Considerations
Key Recommendations
References
1 Vasireddi M, Hilliard J. Herpes B virus, macacine herpesvirus 1, breaks simplex virus tradition via major histocompatibility complex class I expression in cells from human and macaque hosts. Journal of virology 2012. link 2 Kaptein SJ, Jungscheleger-Russell J, Martínez-Martínez P, Beisser PS, Lavreysen H, Vanheel A et al.. Generation of polyclonal antibodies directed against G protein-coupled receptors using electroporation-aided DNA immunization. Journal of pharmacological and toxicological methods 2008. link 3 Mallanna SK, Rasool TJ, Sahay B, Aleyas AG, Ram H, Mondal B et al.. Inhibition of Anatid Herpes Virus-1 replication by small interfering RNAs in cell culture system. Virus research 2006. link 4 Ball MJ, Nuttall K, Warren KG. Neuronal and lymphocytic populations in human trigeminal ganglia: implications for ageing and for latent virus. Neuropathology and applied neurobiology 1982. link 5 Srivastava PC, Pickering MV, Allen LB, Streeter DG, Campbell MT, Witkowski JT et al.. Synthesis and antiviral activity of certain thiazole C-nucleosides. Journal of medicinal chemistry 1977. link